Investigating the effect of prescribing olanzapine on reducing the amount of midazolam and fentanyl and preventing delirium

Investigating the effect of prescribing olanzapine on reducing the amount of midazolam and fentanyl and preventing delirium in patients under mechanical ventilation admitted to the intensive care unit

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240319061337N1

Enrollment

Registered

2024-06-09

Start date

2024-05-21

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

delirium. Delirium due to known physiological condition

Interventions

Intervention 1: In the intervention group, patients receive Olanzapine. It should be noted that the drug Olanzapine will be prescribed at a dose of 2.5 mg twice a day for 3 days and it will be adminis

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Mechanically ventilated patients hospitalized in the intensive care unit.

Exclusion criteria

Exclusion criteria: Patients who have a history of using narcotic drugs. Patients who have a history of taking antipsychotic drugs. Patients who have a history of neurological and psychiatric diseases and neurological/neurosurgical diseases.

Design outcomes

Primary

Measure	Time frame
Delirium score in MDAS questionnaire. Timepoint: for 3 days after the intervention. Method of measurement: The Memorial Delirium Assessment Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAminollah Vasigh

Ilam University of Medical Sciences

aminvasigh1344@gmail.com+98 84 3222 7134

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026